Systemic therapy for cutaneous melanoma.
This article provides a review of the current medical management of patients with high-risk and metastatic cutaneous melanoma, including a review of the use of adjuvant interferon therapy and a discussion of adjuvant treatments under evaluation. The use of standard chemotherapeutic agents for metastatic disease is discussed, with an emphasis on developmental therapeutics using targeted agents. This discussion includes a review of the immune therapy for metastatic melanoma, including newer immunomodulatory agents and cellular therapeutics that are expected to significantly impact the care of these patients.
Treisman
Jonathan
J
Immunotherapy Program, Aurora St Luke's Medical Center, 2900 West Oklahoma Avenue, Milwaukee, WI 53215, USA. jtreisman@gmail.com
Garlie
Nina
N
D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive; D007372:Interferons / Q000627:therapeutic use; D008545:Melanoma / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D012878:Skin Neoplasms / Q000601:surgery / Q000628:therapy*
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007372:Interferons